InvestorsHub Logo
Followers 7
Posts 582
Boards Moderated 0
Alias Born 08/25/2012

Re: None

Friday, 07/08/2022 12:17:39 PM

Friday, July 08, 2022 12:17:39 PM

Post# of 70
The bigger news has been totally ignored:
COPENHAGEN, Denmark, June 28, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Medicines Agency (EMA) has granted access to its priority medicines (PRIME) scheme for MVA-BN® RSV in active immunization for the prevention of lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults ≥60 years of age

$ Bilions in US dollars in sales, maybe after the US announces access is granted the big move comes for this vaccine